Delivery Order SPE2DB22D3004-SPE2DB24FRD51
Award Date
7/23/24
Potential Completion Date
7/24/24
Potential Value
$2K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML to the Defense Logistics Agency (DLA). The fixed-price delivery order, valued at $8,856.30, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on May 14, 2025. The contract has an ultimate completion date of May 15, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award is for $4,212.40 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract is a Delivery Order awarded by the Defense Logistics Agency (DLA), a defense agency, and has a firm fixed price pricing type. The award has a completion date of February 24, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
The federal contract award is for the delivery of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award, valued at $52,789.50, is a Firm Fixed Price delivery order with a completion date of June 16, 2022. This contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $31,939.92, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The $1,684.96 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on June 17, 2025, with a completion date of June 18, 2025. The contract is not set aside and does not mention any subcontractors. AmerisourceBergen Drug Corp holds a substantial $999,999,999.00...
This federal contract award is to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract, valued at $157,728.00, was awarded by the Defense Logistics Agency (DLA) and has a firm fixed-price delivery order contract type with a period of performance through March 28, 2024. The contract award is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery...
This federal contract award to Amerisourcebergen Drug Corp is for the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The $113,657.00 firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of May 22, 2025 and is not set aside. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that serves as a critical supplier of medical and pharmaceutical products to federal agencies,...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $1,577.28, was awarded to AmerisourceBergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of April 17, 2024. AmerisourceBergen Drug Corp...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order valued at $153,284 for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of August 4, 2023. The contract is a firm fixed-price arrangement, and there is no set-aside designation indicated. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $12,212.72, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of May 24, 2024. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The...